HomeCompareBLPH vs SBUX

BLPH vs SBUX: Dividend Comparison 2026

BLPH yields 158.04% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BLPH wins by $32.52M in total portfolio value
10 years
BLPH
BLPH
● Live price
158.04%
Share price
$0.01
Annual div
$0.02
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.68M
Annual income
$14,560,088.59
Full BLPH calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — BLPH vs SBUX

📍 BLPH pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBLPHSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BLPH + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BLPH pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BLPH
Annual income on $10K today (after 15% tax)
$13,433.54/yr
After 10yr DRIP, annual income (after tax)
$12,376,075.30/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, BLPH beats the other by $12,315,609.32/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BLPH + SBUX for your $10,000?

BLPH: 50%SBUX: 50%
100% SBUX50/50100% BLPH
Portfolio after 10yr
$16.43M
Annual income
$7,315,612.53/yr
Blended yield
44.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

BLPH
Analyst Ratings
7
Buy
1
Hold
Consensus: Buy
Altman Z
-77.3
Piotroski
2/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BLPH buys
0
SBUX buys
0
No recent congressional trades found for BLPH or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBLPHSBUX
Forward yield158.04%2.84%
Annual dividend / share$0.02$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$32.68M$167.0K
Annual income after 10y$14,560,088.59$71,136.45
Total dividends collected$30.36M$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: BLPH vs SBUX ($10,000, DRIP)

YearBLPH PortfolioBLPH Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$26,504$15,804.17$11,121$420.68+$15.4KBLPH
2$67,507$39,147.31$12,548$648.40+$55.0KBLPH
3$165,418$93,186.16$14,440$1,013.98+$151.0KBLPH
4$390,402$213,404.75$17,068$1,617.30+$373.3KBLPH
5$888,436$470,705.22$20,912$2,649.52+$867.5KBLPH
6$1,951,729$1,001,103.05$26,875$4,499.29+$1.92MBLPH
7$4,143,713$2,055,363.02$36,771$8,014.12+$4.11MBLPH
8$8,512,033$4,078,259.67$54,542$15,197.11+$8.46MBLPH
9$16,937,387$7,829,511.79$89,602$31,242.49+$16.85MBLPH
10$32,683,093$14,560,088.59$167,011$71,136.45+$32.52MBLPH

BLPH vs SBUX: Complete Analysis 2026

BLPHStock

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Full BLPH Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this BLPH vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BLPH vs SCHDBLPH vs JEPIBLPH vs OBLPH vs KOBLPH vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.